LNP-based delivery of a Toll-like receptor 9 agonist elicits potent adjuvant effects and antitumor immunity
T cells across diverse immunogens. In aggressive B16F10-OVA melanoma and HPV-associated TC-1 tumor models, LNPC-adjuvanted vaccines successfully remodeled the highly suppressive TME, achieving near-complete tumor clearance, significantly prolonged survival, and durable immune memory without inducing off-target systemic toxicity. Ultimately, the LNPC system represents a versatile, highly effective adjuvant platform with substantial clinical translational potential, offering a compelling new strategy for personalized tumor immunotherapy.
Authors
- Renfei Gao (ORCID: https://orcid.org/0000-0003-4867-842X)
- Jialin Xu (ORCID: https://orcid.org/0000-0002-3910-1306)
- S Q Zhang
- Xi Zhang (ORCID: https://orcid.org/0000-0002-4638-3997)
- Yarong Zeng
- Feng Han (ORCID: https://orcid.org/0000-0002-7527-1660)
- Y F Li
- Ningshao Xia
- Lizhi Zhou
- Shaowei Li
- Qingbing Zheng
- Rong Su
- Hai Yu
- Tingting Li
- Ying Gu
Institutions
- Xiamen University (CN)
Publication Details
- Journal
- npj Vaccines
- Published
- 2026-05-09
- DOI
- https://doi.org/10.1038/s41541-026-01465-1
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Fundamental Research Funds for the Central Universities